About World ADC
Network with 650+ of your peers, from 220 organizations, at the industry’s definitive antibody drug conjugate meeting
Antibody-drug conjugate development is not without significant challenges. As a community we’ve learned this the hard way. Earlier this year Seattle Genetics SGN-CD33A reminded us how treacherous the path to a clinically impactful ADC can be.
However, following in the footsteps of Adcetris and Kadcyla, ADCs are entering an exciting new era. In 2016, fifteen novel ADCs entered clinical trials. This year there’s anticipated to be more as well as two new market approved drugs.
Cleaner targets, optimized linker-drug chemistries, translatable animal models and CMC improvements are all contributing to greater promise for patients. These topics and more will be discussed extensively at this year’s World ADC San Diego.
Now in it’s 8th year, World ADC San Diego is the industry’s definitive ADC conference. It’s mission – to be the environment in which scientists can communicate problems and solutions; share novel data and forge networks to develop more clinically impactful ADCs.
Over 3 full days, this multi-tracked conference will address every element of ADC research from early discovery to marketization making it the most comprehensive antibody drug conjugate forum you’ll attend this year.
Join your peers and 81 industry expert speakers at this year’s conference to:
- Explore next generation payloads and linkers technologies with differentiated mechanisms of action
- Improve preclinical ADC predictability to successfully file an IND and effectively translate into the clinic
- Expand ADC therapeutic index by reviewing lessons learned in clinical trial design, dosing regimens and patient stratification
- Advance clinical scale manufacturing with insight to reduce your manufacturing costs, minimize timelines and maximize efficiency
Access this intelligence, and much more, when the ADC community converges in San Diego this fall.